Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Asia Pharma ExpoAsia Pharma Expo
Not Confirmed
Not Confirmed
12-14 February, 2026
Not Confirmed
Not Confirmed
14-17 February, 2026
Suppliers Night ExpoSuppliers Night Expo
Not Confirmed
Not Confirmed
16-17 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Asia Pharma Expo
Not Confirmed
Contact SupplierAsia Pharma Expo
Asia Pharma ExpoAsia Pharma Expo
Industry Trade Show
Not Confirmed
12-14 February, 2026
Industry Trade Show
Not Confirmed
14-17 February, 2026
Suppliers Night ExpoSuppliers Night Expo
Industry Trade Show
Not Confirmed
16-17 February, 2026
Digital content
NEWS #PharmaBuzz
19 Sep 2021
// FIRSTWORDPHARMA
27 Jul 2020
// Polina Ivanova REUTERS
https://www.reuters.com/article/us-health-coronavirus-russia-vaccine/biocad-discussing-potential-covid-19-vaccine-production-in-china-idUSKCN24S1VS
07 Jun 2020
// CGTN
https://news.cgtn.com/news/2020-06-08/Russia-registers-new-drug-to-contain-complications-caused-by-COVID-19-R9vpZzmRs4/index.html
04 Jul 2017
// MANUFACTURING
https://www.manufacturingchemist.com/news/article_page/BIOCAD_rituximab_biosimilar_to_receive_market_authorisation_in_India/131220
05 Jun 2017
// BUSINESSWIRE
http://www.businesswire.com/news/home/20170605005632/en/BIOCAD-registered-rituximab-biosimilar-Bolivia-Honduras/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
10 Mar 2017
// M. Guarnaccia LAW
Drugs in Development
Details:
BCD-281 (Ocrelizumab) is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: BCD-281
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2026
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BCD-281 (Ocrelizumab) is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Product Name : BCD-281
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 06, 2026
Details:
Adalimumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Adalimumab
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2025
Lead Product(s) : Adalimumab
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adalimumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 18, 2025
Details:
BCD-256 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Lead Product(s): BCD-256,Divozilimab
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2025
Lead Product(s) : BCD-256,Divozilimab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Pharmacokinetics, & Immunogenicity of BCD-256-1 & Divozilimab in Lupus Patients
Details : BCD-256 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 22, 2025
Details:
Pegdarbepoetin Beta is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anemia.
Lead Product(s): Pegdarbepoetin Beta
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 13, 2025
Lead Product(s) : Pegdarbepoetin Beta
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BCD-131 + Mircera Safety and Efficacy In CKD Dialysis-Dependent Anemia
Details : Pegdarbepoetin Beta is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 13, 2025
Details:
BCD-236 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.
Lead Product(s): BCD-236,Undsclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2025
Study of BCD-236 with Chemotherapy in Relapsed/Metastatic Triple-Negative Breast Cancer
Details : BCD-236 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 07, 2025
Details:
BCD-261 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colitis, Ulcerative.
Lead Product(s): BCD-261
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 23, 2025
Lead Product(s) : BCD-261
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BCD-261 Safety, PK/PD, Immunogenicity & Efficacy In Moderate-Severe UC
Details : BCD-261 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 23, 2025
Details:
BCD-261 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Crohn Disease.
Lead Product(s): BCD-261
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2025
Lead Product(s) : BCD-261
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BCD-261 Safety, PK/PD, Immunogenicity & Efficacy In Moderate-Severe Crohn’s Disease
Details : BCD-261 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 22, 2025
Details:
Divozilimab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Multiple Sclerosis.
Lead Product(s): Divozilimab
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2025
BCD-132 Safety & Efficacy in Multiple Sclerosis Previously Treated in JSC BIOCAD Trials
Details : Divozilimab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2025
Details:
Eculizumab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hemoglobinuria, Paroxysmal.
Lead Product(s): Eculizumab
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2025
Lead Product(s) : Eculizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BCD-148 Extension Study For PNH Patients Previously Treated In BCD-148-2/NOCTURN
Details : Eculizumab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hemoglobinuria, Paroxysmal.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2025
Details:
BCD-261 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): BCD-261
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024
Lead Product(s) : BCD-261
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BCD-261 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
